

Silymarin vs Hesperidin/Diosmin in Fibromyalgia

NCT07293767

Status	RECRUITING
Phase	Not Applicable
Sponsor	Ain Shams University
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (6)

- Informed written consent.
- Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia: Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 , or WPI 3 to 6 and SS scale score ≥ 9
- Age ≥ 18 years old (males and females)
- Diagnosis of FM confirmed by a rheumatologist.
- Persistent pain syndrome on conventional therapy.

... and 1 more (see full listing online)

Exclusion (8)

- Pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that would confound assessment or self-evaluation of the pain associated with FM.
- Patients with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.
- Allergy to silymarin or diosmin or hesperidin.
- Cognitive deficits that could impair understanding of the study, completion of questionnaires, or adherence to therapy.
- Pregnant or planning pregnancy women and breastfeeding women.

... and 3 more (see full listing online)

Locations (1 total)

Outpatients clinic of department of Internal medicine- Rheumatology unit Ain shams hospitals., Cairo, Egypt